Release Date: 23-Jan-2025
Acasunlimab (GEN1046) is an investigational bispecific antibody developed using Genmab's DuoBodyandreg; technology platform, in collaboration with BioNTech. This first-in-class therapeutic agent targets two immune pathways simultaneously, combining the blockade of PD-L1 with the conditional activation of 4-1BB, a costimulatory receptor on T cells and natural killer (NK) cells. The unique design of Acasunlimab allows it to engage both immune pathways, with its PD-L1 arm binding to the PD-L1 receptor on tumor cells and the 4-1BB arm only activating the immune response when both PD-L1 and 4-1BB are bound. This conditional activation of 4-1BB enhances T-cell and NK cell responses, potentially leading to a potent antitumor effect.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The dual mechanism of Acasunlimab represents an innovative approach to cancer immunotherapy. The PD-L1 blockade helps to prevent tumors from evading immune detection, while the activation of 4-1BB stimulates T cells and NK cells, promoting a more robust immune attack on the tumor. Preclinical studies have shown that Acasunlimab induces superior T-cell proliferation, cytokine production, and antigen-specific cytotoxicity compared to traditional PD-(L)1 antibodies. Additionally, it has demonstrated potent antitumor activity in mouse tumor models, suggesting significant therapeutic potential.
Acasunlimab is currently being evaluated in ongoing clinical trials, including a Phase 3 study for patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after treatment with a checkpoint inhibitor. This clinical investigation is crucial, as it aims to address a clinical gap in treating patients with relapsed or refractory disease, particularly those who have not responded to traditional checkpoint inhibitors. As a potential combination therapy, Acasunlimab could also work synergistically with other checkpoint inhibitors to further enhance antitumor efficacy.
However, in August 2024, BioNTech decided to discontinue its participation in the further development of the Acasunlimab program under the existing collaboration agreement, leaving Genmab to continue advancing the antibody on its own. Despite this change, the ongoing trials and preclinical data suggest that Acasunlimab may offer a promising new option for cancer treatment in the future.